Drilldown: Medicines
Appearance
Medicines > onset
:
Clinical improvement within 24-72 hours
or
TSH normalization 4-8 weeks; symptomatic improvement weeks to months 
:
Clinical improvement within 24-72 hours
or
TSH normalization 4-8 weeks; symptomatic improvement weeks to months 
Use the filters below to narrow your results.
[[:Category:Antifungals|Antifungal (triazole)]] (1) ·
[[:Category:Azalides|Azalide]] (1) ·
[[:Category:Hormone_replacement|Hormone replacement]] (1) ·
[[:Category:Macrolide_antibiotics|Macrolide antibiotic]] (1) ·
[[:Category:Thyroid_hormones|Thyroid hormone]] (1) ·
[[:Category:Triazoles|Triazole]] (1)
'"`UNIQ--vote-00000033-QINU`"', '"`UNIQ--vote-00000034-QINU`"', '"`UNIQ--vote-00000035-QINU`"' (1) ·
'"`UNIQ--vote-000003F6-QINU`"', '"`UNIQ--vote-000003F7-QINU`"', '"`UNIQ--vote-000003F8-QINU`"', '"`UNIQ--vote-000003F9-QINU`"', '"`UNIQ--vote-000003FA-QINU`"', '"`UNIQ--vote-000003FB-QINU`"' (1) ·
'"`UNIQ--vote-00000A42-QINU`"', '"`UNIQ--vote-00000A43-QINU`"', '"`UNIQ--vote-00000A44-QINU`"', '"`UNIQ--vote-00000A45-QINU`"', '"`UNIQ--vote-00000A46-QINU`"' (1)
1.6 mcg/kg/d in young healthy adults; 25-50 mcg/d in elderly or cardiac disease, titrated by TSH at 6-8 weeks (1) ·
500 mg PO day 1, then 250 mg PO daily days 2-5 (Z-Pak); 1 g PO single dose for chlamydia; pediatric dosing 10 mg/kg day 1, 5 mg/kg days 2-5 (1) ·
Vulvovaginal: 150 mg PO single dose; oropharyngeal: 200 mg PO day 1, then 100 mg daily ×14 days; invasive candidiasis: 800 mg load, then 400 mg PO/IV daily; cryptococcal meningitis: 400-800 mg/d (1)
~30 hours (long, supports once-daily dosing and substantial drug-interaction window after discontinuation)'"`UNIQ--ref-00000A47-QINU`"' (1) ·
~68 hours (terminal; reflects deep tissue accumulation, much longer than plasma)'"`UNIQ--ref-000003FC-QINU`"' (1) ·
~7 days (euthyroid); longer in hypothyroidism (~9-10 days), shorter in hyperthyroidism'"`UNIQ--ref-00000036-QINU`"' (1)
40-80% (oral); reduced by food, calcium, iron, PPIs, fiber; take fasting with water'"`UNIQ--ref-00000037-QINU`"' (1) ·
>90% (oral; not affected by food or gastric pH — a major practical advantage over itraconazole)'"`UNIQ--ref-00000A48-QINU`"' (1) ·
~37% (oral; food reduces absorption modestly)'"`UNIQ--ref-000003FD-QINU`"' (1)
None (1) ·
First-line in pregnancy; dose typically increased 25-30% due to estrogen-driven rise in TBG and fetal demand. Lactation safe at physiologic doses.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; commonly used in pregnancy when macrolide indicated.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 3 results in range #1 to #3.

